Finance

Lists
Q2 2026 earnings • released • EPS miss -947.90%
See results
BLSM:NASDAQ
BlossomHill Therapeutics Inc
$27.10
+1.12%
(+0.30) 1D
Sep 22, 11:14:30 AM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BLSM...
Open
$26.37
High
$27.31
Low
$26.37
Mkt. cap
830.44M
Avg. vol.
229.24K
Volume
44.81K
52-wk high
$27.99
52-wk low
$15.25
EPS
-$2.32
No. of employees
63
Open
$26.37
High
$27.31
Low
$26.37
Mkt. cap
830.44M
Avg. vol.
229.24K
Volume
44.81K
52-wk high
$27.99
52-wk low
$15.25
EPS
-$2.32
No. of employees
63
News stories
From web sources and news partners
About BlossomHill Therapeutics Inc
CEO-
Employees63
Founded2020
Headquarters-
SectorPharmaceutical industry
Websitebhtherapeutics.com
Analyst ratings
Based on 5 analysts giving stock ratings to BLSM in the past 3 months
Strong buy
Buy
5
Hold
0
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for BLSM in the last 3 months.
Highest
Current $27.10
$40.00 (+47.60%)
Average
$36.75 (+35.61%)
Lowest
$32.00 (+18.08%)
Analyst
Recommendation
Action
Price target
Projected
Date
Andrew Berens
Leerink Partners
Buy
Maintained
$40.00
+47.6%
09/21/2026
Brian Cheng
J.P. Morgan
Buy
Reiterated
-
-
09/18/2026
Michael Schmidt
Guggenheim
Buy
Maintained
$40.00
+47.6%
09/18/2026
Charles Zhu
LifeSci Capital
Buy
Maintained
$32.00
+18.1%
09/15/2026
Robert Burns
H.C. Wainwright
Buy
Initiated
$35.00
+29.2%
09/01/2026
Last report
Sep 18, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-$8.75 / -$0.84
-947.90%miss
Revenue / Est. (USD)
- / 0.00
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Mar 2025
Mar 2026
Revenue
-
-
Cost of goods sold
-
-
Cost of revenue
-
-
Research and development expenses
9.57M
19.90M
Total research and development expenses
-
-
Selling, general, and admin expenses
1.88M
2.21M
Operating expense
11.45M
22.11M
Total operating expenses
11.45M
22.11M
Operating income
-11.45M
-22.11M
Other non operating income
-
-
EBT including unusual items
-10.48M
-21.01M
EBT excluding unusual items
-10.48M
-21.01M
Income tax expense
-
-
Effective tax rate
-
-
Other operating expenses
-
-
Net income
-10.48M
-21.01M
Net profit margin
-
-
Earnings per share
-
-
Interest and investment income
976.00K
1.10M
Interest expense
-
-
Net interest expenses
976.00K
1.10M
Depreciation and amortization charges
-
-
EBITDA
-11.37M
-21.98M
Gain or loss from assets sale
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps